Seyed Ali Jazayeri-Tehrani

Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial

Seyed Ali Jazayeri-Tehrani, Seyed Mahdi Rezayat, Siavash Mansouri et al. · Nutrition & Metabolism · 2019 · 197 citations · Full text

Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial

Milad Daneshi‐Maskooni, Seyed Ali Keshavarz, Mostafa Qorbani et al. · Nutrition & Metabolism · 2018 · 55 citations · Full text

Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial

Milad Daneshi‐Maskooni, Seyed Ali Keshavarz, Mostafa Qorbani et al. · BMC Complementary and Alternative Medicine · 2019 · 53 citations · Full text

Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol

Seyed Ali Jazayeri-Tehrani, Seyed Mahdi Rezayat, Siavash Mansouri et al. · BMJ Open · 2017 · 37 citations · Full text

The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial

Milad Daneshi‐Maskooni, Seyed Ali Keshavarz, Siavash Mansouri et al. · Trials · 2017 · 35 citations · Full text